Revenio Group Corporation – Changes in management
Revenio Group Corporation, Stock Exchange Release, November 25, 2019 at 9:30 am EET
REVENIO’S CEO CHANGES – TIMO HILDÉN APPOINTED AS ACTING CEO
Revenio Group Cororation’s (“Revenio”, “Group”) Board of Directors and CEO Mikko Moilanen have mutually agreed that Mikko Moilanen leaves his position as the CEO of the Group. The resignation shall take effect immediately.
Revenio’s Board of Directors has appointed Timo Hildén as the acting CEO. He has worked as Revenio Group’s CEO during January 1st, 2017 until July 30, 2019 as well as Revenio’s Group company Icare Finland Oy’s Managing Director during 2012-2017.
The Board of Directors will start the recruitment process for the new CEO immediately.
”Differing views on how the company is to be developed led to this unfortunate outcome”, comments Revenio Group’s Chairman of the Board Pekka Rönkä.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Chairman of the Board Pekka Rönkä, tel. +358 40 826 4356
pekka.ronka@revenio.fi
DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority
Principal media
The Revenio Group in brief
Revenio is a health tech group operating on the international market and a global leader in solutions for the diagnostics of the eye.
The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy, and macular degeneration, and the monitoring of these during the treatment process. Revenio’s Research function focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment.
In 2018, the Revenio Group's net sales totaled EUR 30.7 million, while its EBITDA stood at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.